## Supporting information

Article

# Synthesis and Bioactivity of Thiosemicarbazones containing Adamantane Skeleton

#### Van Hien Pham<sup>1</sup>, Thi Phuong Dung Phan<sup>2</sup>, Dinh Chau Phan<sup>3,\*</sup> and Binh Duong Vu<sup>1,\*</sup>

- <sup>1</sup> Drug R&D center, Vietnam Military Medical University. No.160, Phung Hung str., Phuc La ward, Ha Dong district, Hanoi 100000, Vietnam; phamvanhien181288@gmail.com
- <sup>2</sup> Department of Pharmaceutical Chemistry, Hanoi University of Pharmacy. No. 15, Le Thanh Tong Str., Hoan Kiem district, Hanoi 100000, Vietnam; pdungdhd@gmail.com
- <sup>3</sup> Hanoi University of Science and Technology. No.1, Dai Co Viet str., Bach Khoa ward, Hai Ba Trung district, Hanoi 100000, Vietnam.
- \*Correspondence: chau.phandinh@hust.edu.vn (D.C.P); vbduong2978@gmail.com (B.D.V.); Tel.: +84 983 425 460 (B.D.V); Fax: +84 243 688 4077 (B.D.V.).

### Table of content

Scheme 1. Synthesis of thiosemicarbazones 2a-k and 3a-j	1
Table 1. Melting point (m.p), yield (%), molecular formulae (Mol.For.), molecular weight (Mol. V	Vt.)
and Rf of thiosemicarbazones 2a-k and 3a-j	2
Table 2. Minimum inhibitory concentration (MIC) of synthesized thiosemicarbazones 2a-k and 3a-j	j3
Table 3. IC50 of synthesized thiosemicarbazones 2a-k and 3a-j.	4
Table 4. The effect of newly synthesized thiosemicarbazones 2a-k and 3a-j on the viability of HeP	3B,
Hela, A549, and MCF-7 cells after 48 h of incubation	5
<sup>1</sup> H-NMR spectrum of compound <b>2a</b>	6
<sup>13</sup> C-NMR spectrum of compound <b>2a</b>	6
HMBC spectrum of compound <b>2a</b>	7
HSOC spectrum of compound <b>2a</b>	7
DEPT spectrum of compound <b>2a</b>	8
HR-ESI-MS spectrum of compound <b>2a</b>	8
<sup>1</sup> H-NMR spectrum of compound <b>2b</b>	9
<sup>13</sup> C-NMR spectrum of compound <b>2b</b>	9
ESI-MS spectrum of compound <b>2b</b> (negative)	.10
ESI-MS spectrum of compound <b>2b</b> (positive)	10
<sup>1</sup> H-NMR spectrum of compound <b>2</b> c	11
<sup>13</sup> C-NMR spectrum of compound <b>2</b> c	11
ESLMS spectrum of compound 2c (negative)	12
ESI-MS spectrum of compound 2c (negative)	12
1H-NMR spectrum of compound 2d	12
13C NMR spectrum of compound 2d	12
FSI MS spectrum of compound <b>2d</b> (nogotive)	11
ESI-MS spectrum of compound 2d (negative).	. 14 1/
1H NMP spectrum of compound 2a	15
11-NMR spectrum of compound 2e	.15
ESI MS another of compound 2c (nogetive)	. 15
ESI-MS spectrum of compound 2e (negative)	. 10
ESI-MS spectrum of compound 2e (positive)	.10
<sup>1</sup> H-NMR spectrum of compound 21	.17
ESC MC an a function of compound 21	.1/
ESI-MS spectrum of compound 2f (negative)	.18
ESI-MS spectrum of compound 2f (positive)	.18
<sup>1</sup> H-NMR spectrum of compound 2g	. 19
<sup>13</sup> C-NMR spectrum of compound 2g	. 19
ESI-MS spectrum of compound 2g (negative)	.20
ESI-MS spectrum of compound 2g (positive)	.20
<sup>1</sup> H-NMR spectrum of compound 2 <b>h</b>	.21
<sup>13</sup> C-NMR spectrum of compound <b>2h</b>	.21
ESI-MS spectrum of compound 2h (negative)	.22
ESI-MS spectrum of compound <b>2h</b> (positive)	.22
<sup>1</sup> H-NMK spectrum of compound 21	.23
<sup>13</sup> C-NMK spectrum of compound <b>21</b>	.23
ESI-MS spectrum of compound <b>2i</b> (negative)	.24
ESI-MS spectrum of compound <b>2i</b> (positive)	.24
<sup>1</sup> H-NMR spectrum of compound <b>2j</b>	. 25
<sup>13</sup> C-NMR spectrum of compound <b>2</b> j	. 25
ESI-MS spectrum of compound 2j (negative)	. 26

ESI-MS spectrum of compound 2j (positive)	26
<sup>1</sup> H-NMR spectrum of compound <b>2k</b>	27
<sup>13</sup> C-NMR spectrum of compound <b>2k</b>	27
ESI-MS spectrum of compound 2k (negative)	28
ESI-MS spectrum of compound 2k (positive)	28
<sup>1</sup> H-NMR spectrum of compound <b>3a</b>	29
<sup>13</sup> C-NMR spectrum of compound <b>3a</b>	29
ESI-MS spectrum of compound 3a (negative)	30
ESI-MS spectrum of compound 3a (positive)	30
<sup>1</sup> H-NMR spectrum of compound <b>3b</b>	31
<sup>13</sup> C-NMR spectrum of compound <b>3b</b>	31
ESI-MS spectrum of compound <b>3b</b> (negative)	32
ESI-MS spectrum of compound <b>3b</b> (positive)	32
<sup>1</sup> H-NMR spectrum of compound <b>3c</b>	33
<sup>13</sup> C-NMR spectrum of compound <b>3</b> c	33
ESI-MS spectrum of compound 3c (negative)	34
ESI-MS spectrum of compound 3c (positive)	34
<sup>1</sup> H-NMR spectrum of compound <b>3d</b>	35
<sup>13</sup> C-NMR spectrum of compound <b>3d</b>	35
ESI-MS spectrum of compound 3d (negative)	36
ESI-MS spectrum of compound 3d (positive)	36
<sup>1</sup> H-NMR spectrum of compound <b>3e</b>	37
<sup>13</sup> C-NMR spectrum of compound <b>3e</b>	37
ESI-MS spectrum of compound 3e (negative)	38
ESI-MS spectrum of compound 3e (positive)	38
<sup>1</sup> H-NMR spectrum of compound <b>3f</b>	39
<sup>13</sup> C-NMR spectrum of compound <b>3f</b>	39
ESI-MS spectrum of compound 3f (negative)	40
ESI-MS spectrum of compound 3f (positive)	40
<sup>1</sup> H-NMR spectrum of compound <b>3</b> g	41
<sup>13</sup> C-NMR spectrum of compound <b>3g</b>	41
ESI-MS spectrum of compound 3g (negative)	42
ESI-MS spectrum of compound 3g (positive)	42
<sup>1</sup> H-NMR spectrum of compound <b>3h</b>	43
<sup>13</sup> C-NMR spectrum of compound <b>3h</b>	43
ESI-MS spectrum of compound <b>3h</b> (positive)	44
<sup>1</sup> H-NMR spectrum of compound <b>3i</b>	45
<sup>13</sup> C-NMR spectrum of compound <b>3i</b>	45
ESI-MS spectrum of compound 3i (negative)	46
ESI-MS spectrum of compound 3i (positive)	46
<sup>1</sup> H-NMR spectrum of compound <b>3</b> <i>j</i>	47
<sup>13</sup> C-NMR spectrum of compound <b>3</b> <i>j</i>	47
ESI-MS spectrum of compound 3j (negative)	48
ESI-MS spectrum of compound 3j (positive)	48





**3e**:  $R_1 = H$ ;  $R_2 = 4$ -NO<sub>2</sub>

**3i**:  $R_1 = 3 - NO_2$ ;  $R_2 = 4 - OCH_3$ **3j**:  $R_1 = 3 - NO_2$ ;  $R_2 = 4 - Cl$ 

vvi.) and fit of unobelinearbazones <b>2a</b> K and <b>bu</b> J.									
Comp.	R1	R2	Yield (%)	m.p (°C) Mol.For. (Mol. Wt.)		Rf			
2a	Н	Н	97.0	210.1-212.2	C18H23N3S (313.46)	0.46			
2b	Н	3-NO2	92.7	244.2-246.1	C18H22N4O2S (358.46)	0.38			
2c	Н	4-OCH <sub>3</sub>	95.7	224.5-227.7	C19H25N3OS (343.49)	0.50			
2d	Н	2-OH	95.7	203.8-205.6	C18H23N3OS (329.46)	0.46			
2e	Н	4-NO2	91.3	258.1-260.1	C18H22N4O2S (358.46)	0.43			
2f	Н	$4-OC_2H_5$	95.6	232.2-233.6	C20H27N3OS (357.52)	0.54			
2g	Н	4-Cl	89.6	238.9-239.7	C18H22ClN3S (347.91)	0.68			
2h	2-OH	5-CH3	91.0	241.6-242.5	C19H25N3OS (343.49)	0.54			
2i	3-NO2	$4-OC_2H_5$	61.2	218.7-220.7	C20H26N4O3S (402.51)	0.64			
2j	3-NO2	4-Cl	78.5	252.8-254.0	C18H21ClN4O2S (392.90)	0.53			
2k	2-CH <sub>3</sub>	5-CH3	92.5	212.4-213.8	C20H27N3S (341.52)	0.68			
3a	Н	Н	91.8	231.2-232.7	C19H25N3S (327.49)	0.46			
3b	Н	3-NO2	67.0	251.7-253.5	C19H24N3O2S (372.49)	0.47			
3c	Н	4-Br	65.5	240.9-242.9	C19H24BrN3S (406.39)	0.46			
3d	Н	4-OH	44.3	272.8-273.5	C19H25N3OS (343.49)	0.53			
3e	Н	4-NO2	90.4	266.5-268.9	C19H24N4O2S (372.49)	0.50			
3f	3-NO2	4-Br	17.5	224.5-225.3	C19H23BrN4O2S (451.38)	0.53			
3g	Н	4-Cl	94.0	235.0-236.3	C19H24ClN3S (361.93)	0.58			
3h	Н	4-CH3	73.5	230.3-232.2	C20H27N3S (341.52)	0.36			
3i	3-NO2	4-OCH <sub>3</sub>	69.3	224.6-226.3	C20H26N4O3S (402.51)	0.45			
3j	3-NO2	4-Cl	49.8	250.9-252.4	C19H23ClN4O2S (406.93)	0.54			

**Table 1.** Melting point (m.p), yield (%), molecular formulae (Mol.For.), molecular weight (Mol. Wt.) and Rf of thiosemicarbazones **2a**–k and **3a–j**.

\*Solvent: chloroform/acetone (95/5, *v*/*v*), visualization at UV 254 nm.

	MIC of Synthesized Compounds (µM)								
Comp. No.		Gram (+)		Gram (–)			Fungus		
	EF	SA	BC	EC	PA	SE	CA		
2a	100	25	25	-	-	-	25		
2b	25	50	25	-	-	-	6.25		
2c	12,5	50	100	-	-	-	6.25		
2d	25	-	100	-	100	-	25		
2e	100	50	50	-	-	-	12.5		
2f	50	50	50	-	-	-	25		
2g	25	25	25	-	-	-	6.25		
2h	50	25	50	-	100	-	12.5		
2i	50	50	25	-	-	-	12.5		
2j	50	50	50	-	-	-	25		
2k	100	25	50	-	-	-	12.5		
3a	25	25	50	-	-	-	12.5		
3b	100	25	25	-	-	-	25		
3c	100	100	100	-	-	-	25		
3d	50	50	50	-	-	-	25		
3e	25	25	25	-	-	-	6.25		
3f	25	50	50	-	-	-	25		
3g	25	100	100	-	-	-	25		
3h	50	25	50	-	-	-	12.5		
3i	50	50	50	-	-	-	25		
3ј	100	25	50	-	-	-	12.5		
STM	350	350	175	44	350	175	NT		
CHM	NT	NT	NT	NT	NT	NT	114		

Table 2. Minimum inhibitory concentration (MIC) of synthesized thiosemicarbazones 2a-k and 3a-j.

EF: *Enterococcus faecalis* (ATCC13124); SA: *Staphylococcus aureus* (ATCC25923); BC: *Bacillus cereus* (ATCC 13245); EC: *Escherichia coli* (ATCC25922); PA: *Pseudomonas aeruginosa* (ATCC27853); SE: *Salmonella enterica* (ATCC12228); CA: *Candida albicans* (ATCC10231); STM: streptomycine; CHM: Cycloheximide; NT: not tested; - : inactive.

Comp. No.	IC50 of Synthesized Compounds (µM)								
		Gram (+)		Gram (–)			Fungus		
	EF	SA	BC	EC	PA	SE	CA		
2a	24.78	4.78	4.12	-	-	-	6.78		
2b	10.78	8.99	12.45	-	-	-	3.57		
2c	5.68	9.66	8.24	-	-	-	3.45		
2d	4.89	-	25.22	-	24.67	-	5.35		
2e	25.89	6.78	6.09	-	-	-	5.56		
2f	12.78	7.88	7.82	-	-	-	6.35		
2g	6.78	7.89	6.88	-	-	-	3.24		
2h	11.67	6.24	7.56	-	27.45	-	4.57		
2i	12.78	12.56	12.11	-	-	-	3.57		
2j	6.88	22.67	22.12	-	-	-	4.34		
2k	47.89	6.45	8.49	-	-	-	5.68		
3a	6.34	6.99	12.33	-	-	-	3.67		
3b	25.89	8.99	9.91	-	-	-	7.89		
3c	28.99	50.22	40.45	-	-	-	5.67		
3d	17.89	21.45	25.89	-	-	-	6.78		
3e	4.67	9.23	10.11	-	-	-	3.22		
3f	13.57	21.44	11.88	-	-	-	3.67		
3g	4.78	35.67	32.11	-	-	-	5.34		
3h	12.56	7.88	9.85	-	-	-	6.79		
<b>3i</b>	12.57	15.67	25.62	-	-	-	7.89		
3ј	35.46	6.46	7.49	-	-	-	4.67		

Table 3. IC<sub>50</sub> of synthesized thiosemicarbazones 2a-k and 3a-j.

EF: Enterococcus faecalis ATCC13124; SA: Staphylococcus aureus ATCC25923; BC: Bacillus cereus ATCC

13245; EC: *Escherichia coli* ATCC25922; PA: *Pseudomonas aeruginosa* ATCC27853; SE: *Salmonella enterica* ATCC12228; CA: *Candida albicans* ATCC10231; - : inactive

Comp. No.	Conc.	Hep3B	Hela	A549	MCF-7
	30µM	69.07 ± 1.37	$71.58 \pm 1.49$	$75.40 \pm 1.50$	$58.80 \pm 1.23$
2a	100 µM	$64.47 \pm 0.86$	$60.07 \pm 0.97$	$70.38 \pm 0.94$	$49.35 \pm 0.79$
- 4	30µM	$76.33 \pm 1.79$	$55.29 \pm 1.10$	$83.32 \pm 1.96$	$45.42 \pm 0.91$
2b	100 µM	$70.72 \pm 0.46$	$53.80 \pm 1.41$	$77.20 \pm 0.50$	$43.31 \pm 2.63$
_	30µM	$68.60 \pm 2.74$	$72.09 \pm 2.30$	$76.36 \pm 1.82$	$59.22 \pm 1.89$
2c	100 μM	$59.84 \pm 2.20$	$59.67 \pm 1.43$	$65.32 \pm 2.40$	$49.02 \pm 1.18$
. 1	30µM	$19.34 \pm 2.54$	$61.12 \pm 1.91$	$21.11 \pm 2.78$	$50.21 \pm 1.57$
2d	100 μM	$16.82 \pm 1.60$	$24.55 \pm 1.85$	$18.37 \pm 1.75$	$20.17 \pm 1.52$
•	30µM	$67.73 \pm 1.34$	72.77 ± 2.42	$73.94 \pm 1.46$	$59.79 \pm 1.99$
2e	100 μM	$68.2 \pm 0.63$	$61.01 \pm 1.16$	$74.45 \pm 0.69$	$50.12 \pm 0.95$
26	30µM	$63.5 \pm 1.47$	$69.84 \pm 1.85$	$69.32 \pm 1.61$	$57.38 \pm 1.52$
21	100 µM	$54.53 \pm 1.19$	$57.2 \pm 2.90$	$59.53 \pm 1.30$	$47.00 \pm 2.38$
2-	30µM	$76.83 \pm 2.31$	$71.65 \pm 2.01$	$83.87 \pm 2.52$	$42.50 \pm 2.35$
2g	100 µM	$70.25 \pm 0.41$	$47.90\pm2.03$	$76.69 \pm 0.44$	$39.35 \pm 1.67$
0h	30µM	$23.71 \pm 0.88$	$44.42 \pm 2.35$	$25.88 \pm 0.96$	$36.50 \pm 1.93$
211	100 µM	$21.86 \pm 0.20$	$34.76 \pm 1.36$	$23.86 \pm 0.22$	$28.55 \pm 1.12$
2:	30µM	$78.88 \pm 2.63$	$64.37 \pm 1.47$	$86.11 \pm 2.88$	$52.89 \pm 1.21$
21	100 µM	$76.06 \pm 0.27$	$61.40\pm0.17$	$83.03 \pm 0.29$	$50.45\pm0.14$
2:	30µM	$65.01 \pm 2.17$	$46.16\pm0.38$	$70.97 \pm 2.37$	$37.92\pm0.31$
2 <b>j</b>	100 µM	$62.83 \pm 2.23$	$40.66 \pm 1.04$	$68.59 \pm 2.43$	$33.40\pm0.86$
21	30µM	$67.46 \pm 1.69$	$69.88 \pm 2.12$	$73.64 \pm 1.84$	$57.41 \pm 1.74$
ZK	100 µM	$46.78\pm0.21$	$55.18 \pm 2.92$	$51.06\pm0.23$	$45.33 \pm 2.40$
3a	30µM	$72.06 \pm 1.92$	$74.40 \pm 1.07$	$78.67 \pm 2.09$	$61.12\pm0.88$
	100 µM	$67.93 \pm 1.11$	$69.77 \pm 0.35$	$74.16 \pm 1.22$	$57.32 \pm 0.29$
3h	30µM	$75.15 \pm 0.36$	$70.17 \pm 1.90$	$82.04\pm0.40$	$57.64 \pm 1.56$
50	100 µM	$71.76\pm0.48$	$68.65 \pm 2.51$	$78.34 \pm 0.52$	$56.40 \pm 2.06$
30	30µM	$85.76 \pm 2.42$	$81.90\pm2.11$	$93.62 \pm 2.64$	$67.28 \pm 1.74$
50	100 µM	$68.37 \pm 1.58$	$64.27\pm2.47$	$74.63 \pm 1.73$	$52.80 \pm 2.03$
3d	30µM	$80.15 \pm 1.68$	$81.46 \pm 1.60$	$87.5 \pm 1.83$	$66.92 \pm 1.31$
0 u	100 µM	$72.57 \pm 1.83$	$73.28 \pm 2.50$	$79.22 \pm 2.00$	$60.20 \pm 2.05$
3e	30µM	$67.02 \pm 1.37$	$80.59 \pm 1.39$	$73.17 \pm 1.49$	$66.21 \pm 1.14$
	100 µM	$53.79 \pm 0.71$	$77.66 \pm 0.29$	$58.72 \pm 0.77$	$63.80 \pm 0.24$
3f	30µM	$72.26 \pm 1.01$	$77.05 \pm 2.19$	$78.89 \pm 1.11$	$63.30 \pm 1.80$
	100 µM	$65.95 \pm 0.25$	$67.78 \pm 1.64$	$71.99 \pm 0.28$	$55.68 \pm 1.35$
3g	30µM	$80.42 \pm 1.16$	$62.38 \pm 0.71$	$87.79 \pm 1.27$	$51.25 \pm 0.58$
	100 µM	$70.65 \pm 1.77$	$51.23 \pm 0.49$	$77.13 \pm 1.94$	$42.09 \pm 0.40$
3h	30µM	$75.08 \pm 1.11$	$81.90 \pm 1.04$	$81.96 \pm 1.21$	$67.28 \pm 0.85$
3i	100 μM	$67.16 \pm 2.57$	$75.92 \pm 1.60$	$73.31 \pm 2.81$	$62.37 \pm 1.31$
	30µM	$78.34 \pm 0.71$	$77.12 \pm 2.03$	$85.52 \pm 0.77$	$63.36 \pm 1.67$
	100 μM	$74.04 \pm 0.61$	$56.81 \pm 1.81$	$80.83 \pm 0.67$	$46.67 \pm 1.49$
3j	30µM	69.54 ± 2.39	87.18 ± 1.91	75.92 ± 2.61	$71.62 \pm 1.57$
	100 μM	$61.25 \pm 2.24$	$74.51 \pm 2.17$	$66.86 \pm 2.45$	$61.21 \pm 1.78$
CPT*	0.3 μM	69.56 ± 1.27	$57.06 \pm 1.35$	$67.68 \pm 1.88$	$56.68 \pm 0.68$
	14.4 µM	$37.65 \pm 1.21$	$18.61 \pm 0.56$	$26.74 \pm 2.16$	$28.89 \pm 1.07$

**Table 4.** The effect of newly synthesized thiosemicarbazones **2a-k** and **3a-j** on the viability of HeP3B, Hela, A549, and MCF-7 cells after 48 h of incubation.

\*Camptothecine. Data is presented as percentage of the cell viability  $\pm$  SD.











### <sup>1</sup>H-NMR spectrum of compound **2b**







ESI-MS spectrum of compound **2b** (positive)



#### <sup>1</sup>H-NMR spectrum of compound **2c**





#### <sup>1</sup>H-NMR spectrum of compound **2d**





### <sup>1</sup>H-NMR spectrum of compound **2e**

























300

307.9

190.8

151.9

150

0.0-

209.8

200

250

342.0

350

326.0

356.9 371.0

400

485.0

m/z

450







ESI-MS spectrum of compound 2j (negative)







### <sup>1</sup>H-NMR spectrum of compound 3a





#### <sup>1</sup>H-NMR spectrum of compound **3b**









#### <sup>1</sup>H-NMR spectrum of compound **3d**







![](_page_40_Figure_0.jpeg)

![](_page_40_Figure_1.jpeg)

#### <sup>1</sup>H-NMR spectrum of compound **3f**

![](_page_41_Figure_1.jpeg)

![](_page_42_Figure_0.jpeg)

#### <sup>1</sup>H-NMR spectrum of compound **3g**

![](_page_43_Figure_1.jpeg)

![](_page_44_Figure_0.jpeg)

S42

#### <sup>1</sup>H-NMR spectrum of compound **3h**

![](_page_45_Figure_1.jpeg)

![](_page_46_Figure_0.jpeg)

S44

![](_page_47_Figure_0.jpeg)

![](_page_48_Figure_0.jpeg)

![](_page_49_Figure_0.jpeg)

![](_page_50_Figure_0.jpeg)

![](_page_50_Figure_1.jpeg)